Schlieren (Zurich), Switzerland, 12 April 2011 / b3c newswire /- Neurotune AG, a Swiss biopharmaceutical company, today announced personnel changes in its board of directors as well as management. Dr. Raimund Eckel will form the Board of Directors together Mr. Gerhard Musshafen and Dr. Bruno Oesch (Chairman). Furthermore, Dr. Armin W. Mäder, former CFO of Neurotune assumes the CEO position of Neurotune from Dr. Bruno Oesch who will focus more on strategic as well as business development. These changes will enhance and streamline the management capabilities to achieve Neurotune’s ambitious targets in neuropathic pain and sarcopenia.
Dr. Raimund Eckel joined the board of directors of Neurotune AG. Raimund Eckel studied biology and chemistry at the Universities of Münster and Kiel and received his PhD from the Max Planck Institute in Ploen, Germany. From 1976 through 1999 he ran various international business functions at Boehringer Mannheim, Hoffman-La Roche, Oxochemie and Noxxon pharmaceuticals with operational (Head Medical Marketing & International Product Management, Country President US, Europe and Japan) and strategic responsibilities (Corporate Strategy and Business Development). From 2002 through 2010 he worked as CEO of a management consulting company focused on healthcare before founding his own consulting company, Eckel & Partners Healthcare Consulting in Basel, Switzerland with a specific focus on BD&L and M&A.
Dr. Armin Mäder has several years of experience in banking and biotech companies, and he is also co-founder of a medtech company. He was head of projects for Prosthetics at Institut Straumann AG. Prior to that he was the CFO/COO of the biotech start-up company AC Immune SA in Lausanne, Switzerland where he successfully completed a major financing round as well as a major licensing deal. Armin Mäder started his professional career in the UBS Investment Bank where he has worked in business development, business management and has delivered several time critical multi-million projects and business initiatives. Armin Mäder holds an M.B.A. from IMD in Lausanne and a PhD in Molecular Biology and Biophysics from the ETH Zurich .
About Neurotune AG - www.neurotune.com
Neurotune develops medications to treat disorders of the human nervous system and is developing treatments, which modulate (tune) the connections between nerve cells and their target cells. The Company is developing a strong pipeline of drugs targeting large, growing markets where there is significant unmet medical need, including chronic pain and sarcopenia, the age-related loss of muscle mass which will affect over 3% of the total world population by 2015. Neurotune employs a strong multi-disciplinary team of 14 people. It was incorporated in January 2005 and is domiciled in Schlieren-Zürich, Switzerland.
For more information, contact:
Neurotune AG
Dr. Armin W. Mäder
CEO
Wagistrasse 27a 8952 Schlieren
Phone +41 44 200 21 95
Fax +41 44 200 21 80
ceo@neurotune.com
Media
Dr. Bruno Oesch
Executive Chairman / media relations
Wagistrasse 27a 8952 Schlieren
Phone +41 44 200 21 95
Fax +41 44 200 21 80
bd@neurotune.com